Researchers have developed a novel CRISPR-based method to better understand genetic mutations in IPDs, a differential diagnosis for FNAIT.
Researchers found that maternal anti-αIIb antibodies directly target fetal hematopoietic stem cells (HSCs) in mice models of FNAIT.
A targeted immunotherapy using a specially designed fusion protein for the treatment of FNAIT has shown early promise in animal models.
Biologics like nipocalimab will soon offer a targeted approach that could transform FNAIT prevention and management.
Advancements in the preparation of platelet concentrates, often required to treat FNAIT, have the potential to improve patient care.
IVIG can prevent severe thrombocytopenia in pregnancies complicated with FNAIT, but its efficacy can vary from pregnancy to pregnancy.
A recent study showed that specific imaging patterns could help physicians determine the cause of neonatal brain bleeds.
Subamniotic hemorrhage, a possible FNAIT complication, poses significant diagnostic challenges, particularly when it presents before birth.
Families of patients with NICU stays due to severe conditions reported telemedicine appointments improved adaptation after discharge.
The addition of a sugar molecule (fucosylation) to IgG antibodies could help in determining the severity of alloimmune diseases like FNAIT.
